What is the future of gene therapies? In this episode of Bioprocessing Unfiltered, host Susan D’Costa, chief technical and commercial officer of Genezen, and Phillip Ramsey, CTO of Sangamo Therapeutics, discuss a variety of topics about gene therapies, including what will transform viral vector gene therapy, the evolving role of contract development and manufacturing organizations (CDMOs), and how gene editing in general fits into the broader gene therapy landscape. Plus, they cover the three key factors that are important in a relationship with a CDMO and the onslaught of different pressures that cell and gene therapies are currently under—and how to rekindle confidence in managing that pressure and tackling challenges.
Bioprocessing Unfiltered: Covering both upstream and downstream processing, analytics, AI and digitization, cell and gene therapy and more, Bioprocessing Unfiltered is your insider’s pass to the researchers tackling—and solving—the day-to-day challenges in the bioprocessing industry.
